

Experience.Insight.Vision.

# **NEULAND LABORATORIES LIMITED**

Registered Office: Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

# UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2013

### PART - I

Amount in ₹ Million

	Amount in ₹ Million				
SI.	Particulars		Quarter Ended	1000-00-00-00-00-00-00-00-00-00-00-00-00	Year
No.		30.06.2013	31.03.2013	30.06.2012	Ended
		(Unaudited)	(Unaudited)	(Unaudited)	31.03.2013
Ì					(Audited)
1	Income from Operations				
	(a) Net Sales / Income from Operations	1,213.18	1,096.15	1,266.04	4,605.86
	(b) Other Operating Income	7.21	8.41	13.95	33.18
	Total Income from Operations (Net)	1,220.39	1,104.56	1,279.99	4,639.04
2	Expenses				
	(a) Consumption of Raw Materials	635.29	598.89	752.79	2,726.06
	(b) Changes in inventories of finished goods	46.57	26.26	45.72	(34.50)
	and work in process	40.57	20.20	43.72	(54.50)
	(c) Employee Benefit Expense	96.35	97.28	85.90	348.83
	(d) Depreciation	36.52	35.65	37.26	146.22
	(e) Manufacturing Expenses	122.94	149.57	110.65	482.98
	(f) Other Expenses	91.01	108.34	107.25	468.76
	Total Expenses	1,028.68	1,015.99	1,139.57	4,138.35
3	Profit from Operations before Foreign Exchange (gain)	191.71	88.57	140.42	F00.50
	/ loss and Finance Costs (1-2)	191./1	00.57	140.42	500.69
4	Foreign Exchange (gain) / loss (Net)	22.23	(4.71)	21.97	32.46
5	Profit from Operations before Finance Costs (3-4)	169.48	93.28	118.45	468.23
6	Finance Costs	59.01	64.94	79.68	313.30
7	Profit / (Loss) before Tax (5-6)	110.47	28.34	38.77	154.93
8	Tax Expense				
	(a) Current tax	21.05	5.84	7.97	30.19
	(b) Deferred Tax	32.36	34.02	:-	41.87
	(c) MAT Credit entitlement	(21.05)	(53.50)	-	(53.50)
9	Net Profit / (Loss) for the period (7-8)	78.11	41.98	30.80	136.37
10	Paid-up Equity Share Capital	77.16	77.16	77.16	77.16
11	Reserves excluding Revaluation Reserve as per balance				000.33
	sheet of previous accounting year				898.33
12	Earnings per Share (EPS) (in ₹)				
	(a) Basic	10.22	5.49	4.03	17.84
	(b) Diluted	10.21	5.49	4.03	17.82





SE	GMENT INFORMATION			
SEGMENT REVENUE (NET SALES)	Quarter Ended	Quarter Ended	Quarter Ended	Year
Particulars	30.06.2013	31.03.2013	30.06.2012	Ended
	(Unaudited)	(Unaudited)	(Unaudited)	31.03.2013
				(Audited)
(a) India	278.50	400.17	378.97	1,282.77
(b) Other than India	934.68	695.98	887.07	3,323.09
Total	1,213.18	1,096.15	1,266.04	4,605.86

PAR	PART - II				
SI.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year
No.		30.06.2013	31.03.2013	30.06.2012	Ended
		(Unaudited)	(Unaudited)	(Unaudited)	31.03.2013
					(Audited)
Α	PARTICULARS OF SHARE HOLDING				
1	Public Shareholding				
	(a) Number of Shares	3,817,199	3,817,199	4,156,699	3,817,199
	(b) Percentage of Shareholding	49.93%	49.93%	54.37%	49.93%
2	Promoters and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	-Number of Shares	200,000	200,000	200,000	200,000
	-Percentage of Shares (as a % of the total				
	shareholding of promoter and promoter group)	5.22%	5.22%	5.73%	5.22%
	-Percentage of Shares (as a % of the total share	2.62%	2.62%	2.62%	2.62%
	capital of the Company)				
	(b) Non-encumbered			2 200 270	2 627 770
	-Number of Shares	3,627,779	3,627,779	3,288,279	3,627,779
	-Percentage of Shares (as a % of the total				0.4.700/
	shareholding of promoter and promoter group)	94.78%	94.78%	94.27%	94.78%
1					
	-Percentage of Shares (as a % of the total share	47.45%	47.45%	43.01%	47.45%
	capital of the Company)				

## **B INVESTOR COMPLIANTS**

Particulars	Quarter Ended 30.06.2013
Pending at the beginning of the quarter	0
Received during the quarter	4
Disposed off during the quarter	3
Remaining unresolved at the end of the quarter	1





### **NOTES:**

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 1, 2013, and approved and taken on record at the Board of Directors meeting held on August 2, 2013.
- 2 EPS for the quarters is not annualised.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard AS 17 "Segment Reporting".
- 4 Figures for the quarter ended March 31, 2013, are the balancing figures between the audited figures in respect of the financial year ended March 31, 2013 and the published year to date figures up to the quarter ended December 31, 2012.
- 5 Previous quarter / year figures have been regrouped wherever necessary.

By Order of the Board For Neuland Laboratories Limited

Dr. D.R.Rao

**Chairman & Managing Director** 

Place: Hyderabad Date: August 2, 2013

# K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

#F-7 Laxmi Mills Shakti Mills Lane (Off Dr E Moses Rd)

Mahalaxmi Mumbai 400 011 India Tel: 91 22 2493 2502 / 6655 1770

Fax: 91 22 6655 1774 Grams: VERIFY www.KSAiyar.com Mail@KSAiyar.com

To, **The Board of Directors, Neuland Laboratories Limited**Sanali Info Park, 'A' Block, Ground Floor,
8-2-120/113, Rd No 2, Banjara Hills,
Hyderabad – 500 034

Re: Limited Review of the unaudited financial results for the quarter ended June 30, 2013.

#### 1. Introduction

We have reviewed the accompanying statement of unaudited financial results of **Neuland Laboratories Limited** for the quarter ended June 30, 2013 except for the disclosures regarding 'public shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

# 2. Scope of Review

We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

## 3. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K. S. Aiyar & Co., Chartered Accountants Registration No. 106186W

Raghuvir M. Aiyar

Partner

Membership No: 38128

Place: Hyderabad Date: August 02, 2013

Offices also at Chennai Kolkata Goa Bangalore Coimbatore